Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.

Aleksandar VidenovicAmy W AmaraCynthia ComellaPaula K SchweitzerHelene EmsellemKris LiuAmanda L SterkelMildred D GottwaldJoshua R SteinermanPhilip JochelsonKatie ZomorodiRobert A Hauser

Published in: Movement disorders : official journal of the Movement Disorder Society (2021)

Safety/tolerability was consistent with solriamfetol's known profile. There were no significant improvements on ESS; MWT results suggest possible benefit with solriamfetol in PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

obstructive sleep apnea
sleep quality
open label
study protocol
phase iii
clinical trial
phase ii
positive airway pressure
sleep apnea
weight gain
double blind
depressive symptoms
randomized controlled trial
physical activity
systematic review
placebo controlled
meta analyses